标题
Unique features of trabectedin mechanism of action
作者
关键词
Trabectedin, Pharmacology, Transcription, DNA repair
出版物
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 77, Issue 4, Pages 663-671
出版商
Springer Nature
发表日期
2015-12-14
DOI
10.1007/s00280-015-2918-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study†
- (2015) B. J. Monk et al. ANNALS OF ONCOLOGY
- The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
- (2015) José Luis Ordóñez et al. Oncotarget
- Ecteinascidin 743 Interferes with the Activity of EWS-FLI1 in Ewing Sarcoma Cells
- (2015) Patrick J. Grohar et al. NEOPLASIA
- Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study
- (2014) S. Delaloge et al. ANNALS OF ONCOLOGY
- Molecular Precision Chemotherapy: Overcoming Resistance to Targeted Therapies?
- (2014) Stefan Burdach CLINICAL CANCER RESEARCH
- Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment
- (2014) Carlos Galmarini et al. Marine Drugs
- Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway
- (2013) Sandra Martínez et al. BRITISH JOURNAL OF PHARMACOLOGY
- Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
- (2013) Giovanni Germano et al. CANCER CELL
- Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth
- (2013) Patrick J. Grohar et al. CLINICAL CANCER RESEARCH
- Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial
- (2013) Bradley J. Monk et al. GYNECOLOGIC ONCOLOGY
- Mode of action of trabectedin in myxoid liposarcomas
- (2013) S Di Giandomenico et al. ONCOGENE
- A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
- (2012) Axel Le Cesne et al. EUROPEAN JOURNAL OF CANCER
- Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma
- (2012) Aleksandar Boro et al. INTERNATIONAL JOURNAL OF CANCER
- PPARγ agonists enhance ET-743–induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma
- (2012) Elizabeth Charytonowicz et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma
- (2011) A. Gronchi et al. ANNALS OF ONCOLOGY
- FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons
- (2011) Lisa A. Kachnic et al. CANCER LETTERS
- XPF-Dependent DNA Breaks and RNA Polymerase II Arrest Induced by Antitumor DNA Interstrand Crosslinking-Mimetic Alkaloids
- (2011) Sascha Feuerhahn et al. CHEMISTRY & BIOLOGY
- Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study
- (2011) P. Schöffski et al. EUROPEAN JOURNAL OF CANCER
- Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
- (2011) D. G. Soares et al. MOLECULAR CANCER THERAPEUTICS
- Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations
- (2011) Juan A. Bueren-Calabuig et al. NUCLEIC ACIDS RESEARCH
- Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
- (2010) G. Germano et al. CANCER RESEARCH
- A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature
- (2010) Jeffrey D. Hancock et al. CELL CYCLE
- Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors
- (2010) R. Frapolli et al. CLINICAL CANCER RESEARCH
- Downregulation of XPF–ERCC1 enhances cisplatin efficacy in cancer cells☆
- (2010) Sanjeevani Arora et al. DNA REPAIR
- Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
- (2010) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- A Review of Trabectedin (ET-743): A Unique Mechanism of Action
- (2010) Maurizio D'Incalci et al. MOLECULAR CANCER THERAPEUTICS
- Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours
- (2009) C. Sessa et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
- (2009) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
- (2009) C. Forni et al. MOLECULAR CANCER THERAPEUTICS
- Development of Yondelis® (trabectedin, ET-743). A semisynthetic process solves the supply problem
- (2009) Carmen Cuevas et al. NATURAL PRODUCT REPORTS
- Von Hippel-Lindau-Coupled and Transcription-Coupled Nucleotide Excision Repair-Dependent Degradation of RNA Polymerase II in Response to Trabectedin
- (2008) G. J. Aune et al. CLINICAL CANCER RESEARCH
- Role of homologous recombination in trabectedin-induced DNA damage
- (2008) M. Tavecchio et al. EUROPEAN JOURNAL OF CANCER
- Transcription-coupled DNA Double-Strand Breaks Are Mediated via the Nucleotide Excision Repair and the Mre11-Rad50-Nbs1 Complex
- (2008) Josée Guirouilh-Barbat et al. MOLECULAR BIOLOGY OF THE CELL
- Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin
- (2008) J. A. Casado et al. MOLECULAR CANCER THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More